Elevated Circulating Pigment Epithelium-Derived Factor Predicts the Progression of Diabetic Nephropathy in Patients With Type 2 Diabetes

Context: Pigment epithelium-derived factor (PEDF), a circulating glycoprotein with antiangiogenic, antioxidative, and anti-inflammatory properties, protects against diabetic nephropathy (DN) in animal models. Objective: We investigated whether circulating PEDF predicted the progression of DN in a 4-year prospective study. Design, Setting, and Participants: Baseline plasma PEDF levels were measured in type 2 diabetic subjects recruited from the Hong Kong West Diabetes Registry. The role of PEDF in predicting chronic kidney disease (CKD) and albuminuria progression was analyzed using Cox regression analysis. Main Outcome Measure: We evaluated CKD progression, defined as deterioration in CKD staging and a 25% or greater drop in estimated glomerular filtration rate (eGFR) according to International Society of Nephrology statements. Results: At baseline, plasma PEDF levels increased progressively with CKD staging (P for trend <.001; n = 1136). Among 1071 subjects with baseline CKD stage ≤3, plasma PEDF levels were significantly higher in those with CKD progression (n = 171) during follow-up than those without (P < .001). Baseline PEDF was independently associated with CKD progression (hazard ratio = 2.76; 95% confidence interval = 1.39–5.47; P = .004), adjusted for age, sex, waist circumference, diabetes duration, hemoglobin A1c, systolic blood pressure, use of antihypertensive drugs, C-reactive protein, and eGFR. Elevated baseline PEDF was also associated with the development of microalbuminuria/albuminuria in a subgroup with normoalbuminuria and eGFR >60 mL/min/1.73 m2 (n = 462) at baseline (hazard ratio = 2.75; 95% confidence interval = 1.01–7.49; P < .05), even after adjustment for potential confounders. Conclusions: Elevated PEDF levels may represent a compensatory change in type 2 diabetic patients with renal disease and appear to be a useful marker for evaluating the progression of DN.

[1]  A. Jenkins,et al.  Clinical correlates of serum pigment epithelium-derived factor in type 2 diabetes patients. , 2014, Journal of diabetes and its complications.

[2]  A. Gvritishvili,et al.  Protective role of small pigment epithelium-derived factor (PEDF) peptide in diabetic renal injury. , 2013, American journal of physiology. Renal physiology.

[3]  A. Levin,et al.  Practice Guideline , 2020, Encyclopedia of Behavioral Medicine.

[4]  Y. Bao,et al.  Serum pigment epithelium-derived factor levels are independently correlated with the presence of coronary artery disease , 2013, Cardiovascular Diabetology.

[5]  V. Basevi.  Standards of Medical Care in Diabetes—2013 , 2012, Diabetes Care.

[6]  J. Coresh,et al.  Short-term change in kidney function and risk of end-stage renal disease. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[7]  J. Coresh,et al.  One-Year Change in Kidney Function Is Associated with an Increased Mortality Risk , 2012, American Journal of Nephrology.

[8]  E. Janus,et al.  Plasma concentration of pigment epithelium‐derived factor is closely associated with blood pressure and predicts incident hypertension in Chinese: a 10‐year prospective study , 2012, Clinical endocrinology.

[9]  S. Yamagishi,et al.  Pigment epithelium-derived factor (PEDF) blocks advanced glycation end products (AGEs)-RAGE-induced suppression of adiponectin mRNA level in adipocytes by inhibiting NADPH oxidase-mediated oxidative stress generation. , 2011, International journal of cardiology.

[10]  T. Imaizumi,et al.  Serum level of pigment epithelium-derived factor is a marker of atherosclerosis in humans. , 2011, Atherosclerosis.

[11]  D. Lamers,et al.  Pigment epithelium-derived factor (PEDF) is one of the most abundant proteins secreted by human adipocytes and induces insulin resistance and inflammatory signaling in muscle and fat cells , 2011, International Journal of Obesity.

[12]  S. Miura,et al.  Significance of Plasma Levels of Pigment Epithelium-Derived Factor as Determined by Multidetector Row Computed Tomography in Patients with Mild Chronic Kidney Disease and/or Coronary Artery Disease , 2011, The Journal of international medical research.

[13]  M. Schiffer,et al.  The role of metabolic and haemodynamic factors in podocyte injury in diabetes , 2011, Diabetes/metabolism research and reviews.

[14]  S. Yamagishi,et al.  Pigment epithelium-derived factor (PEDF) inhibits proximal tubular cell injury in early diabetic nephropathy by suppressing advanced glycation end products (AGEs)-receptor (RAGE) axis. , 2011, Pharmacological research.

[15]  V. Basevi.  Diagnosis and Classification of Diabetes Mellitus , 2011, Diabetes Care.

[16]  E. Janus,et al.  Plasma level of pigment epithelium-derived factor is independently associated with the development of the metabolic syndrome in Chinese men: a 10-year prospective study. , 2010, The Journal of clinical endocrinology and metabolism.

[17]  S. Yamagishi,et al.  Pigment epithelium-derived factor inhibits advanced glycation end product-elicited mesangial cell damage by blocking NF-kappaB activation. , 2010, Microvascular research.

[18]  Y. Bao,et al.  Urinary Pigment Epithelium-Derived Factor as a Marker of Diabetic Nephropathy , 2010, American Journal of Nephrology.

[19]  S. Yamagishi,et al.  Positive association of circulating levels of advanced glycation end products (AGEs) with pigment epithelium-derived factor (PEDF) in a general population. , 2010, Pharmacological research.

[20]  F. Gao,et al.  Plasma sRAGE is not associated with urinary microalbumin excretion in type 2 diabetic nephropathy at the early stage. , 2010, Diabetes research and clinical practice.

[21]  D. James,et al.  Pigment epithelium-derived factor contributes to insulin resistance in obesity. , 2009, Cell metabolism.

[22]  C. Schmid,et al.  A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.

[23]  S. Yamagishi,et al.  Serum levels of pigment epithelium‐derived factor (PEDF) are positively associated with visceral adiposity in Japanese patients with type 2 diabetes , 2009, Diabetes/metabolism research and reviews.

[24]  A. Jenkins,et al.  Increased serum pigment epithelium derived factor levels in Type 2 diabetes patients. , 2008, Diabetes research and clinical practice.

[25]  H. Koga,et al.  Pigment epithelium-derived factor (PEDF) ameliorates advanced glycation end product (AGE)-induced hepatic insulin resistance in vitro by suppressing Rac-1 activation. , 2008, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[26]  M. Matsumura,et al.  Relationship between pigment epithelium-derived factor (PEDF) and renal function in patients with diabetic retinopathy , 2008, Molecular vision.

[27]  Ying Chen,et al.  Anti-inflammatory effects of pigment epithelium-derived factor in diabetic nephropathy. , 2008, American journal of physiology. Renal physiology.

[28]  Y. Li,et al.  Improved GFR estimation by combined creatinine and cystatin C measurements. , 2007, Kidney international.

[29]  W. Jia,et al.  [Change and significance of serum pigment epithelium-derived factor in type 2 diabetic nephropathy]. , 2007, Zhonghua yi xue za zhi.

[30]  M. Matsumura,et al.  Plasma concentration of pigment epithelium-derived factor in patients with diabetic retinopathy. , 2007, The Journal of clinical endocrinology and metabolism.

[31]  Tom Greene,et al.  Using Standardized Serum Creatinine Values in the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate , 2006, Annals of Internal Medicine.

[32]  R. Mott,et al.  Salutary Effect of Pigment Epithelium–Derived Factor in Diabetic Nephropathy , 2006, Diabetes.

[33]  G. Lang,et al.  Low content of the natural ocular anti-angiogenic agent pigment epithelium-derived factor (PEDF) in aqueous humor predicts progression of diabetic retinopathy , 2003, Diabetologia.

[34]  W. Benedict,et al.  Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. , 1999, Science.

[35]  K. Asanuma,et al.  PEDF inhibits AGE-induced podocyte apoptosis via PPAR-gamma activation. , 2013, Microvascular research.

[36]  D. Stejskal,et al.  Pigment epithelium‐derived factor as a new marker of metabolic syndrome in Caucasian population , 2010, Journal of clinical laboratory analysis.

[37]  Ying Chen,et al.  Decreased expression of pigment epithelium-derived factor is involved in the pathogenesis of diabetic nephropathy. , 2005, Diabetes.